039200

Oscotec Inc. is a biotechnology company engaged in the discovery and development of synthetic new drugs, functional materials, and dental bone grafts. The company operates three main business segments: new drug development, functional materials and related products, and dental bone grafts. Its drug pipeline includes candidates for oncology, autoimmune diseases, and neurodegenerative disorders, with Lazertinib approved for non-small cell lung cancer and Cevidoplenib in development for immune thrombocytopenia. The company also markets bone graft materials such as BioCera-F, SynCera, and InduCera, as well as resorbable collagen membranes including CollaGuide and LysoGide. Oscotec serves domestic and international markets, with products sold through distributors and direct sales channels. The company collaborates with global pharmaceutical partners for the development and commercialization of its drug candidates. Founded in 1998, Oscotec was formerly known as OCT Inc. and has established subsidiaries including Ectodor Therapeutics Inc. and GENOSCO.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage oscotec.com
Sector Healthcare IR page oscotec.com/investors
Tags
oncology, autoimmune diseases, neurodegenerative diseases, bone grafts, dental materials, synthetic drugs, targeted therapy, immunology, Lazertinib, Cevidoplenib, Adel-Y01, BioCera-F, SynCera, InduCera, CollaGuide, LysoGide, Ectodor Therapeutics Inc., GENOSCO, OCT USA Inc., Oscotec Central R&D Center
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 33.9%
ROI 28.9%
ROIC 28.7%
Profit margin 52.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 46.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 99.839B 34.008B 4.951B 5.062B 3.903B 43.471B 4.369B 18.703B 3.908B 3.554B 18.336B 17.11B 21.859B
Net profit 52.343B 876.527M -24.28B -24.43B -26.263B -4.357B -22.436B 3.471B -5.857B -3.646B 395.029M -2.022B -3.971B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 5.65B 3.91B 19.2B 547M 25.2B 663M 1.86B 2.02B 35.3B 87.6B
↳ YoY growth +46.8% -30.8% +391.2% -97.2% +4,497.1% -97.4% +180.8% +8.5% +1,650.3% +148.1%
↳ 5y CAGR +44.7% -30.4% +45.6% -34.9% -13.8% -36.3% +130.1% +28.4%
Borrowings, current (KRW) 8.47B 11.1B 9.16B 4.8B — 6B 9.29B 6B 13.6B 15.5B
Borrowings, non-current (KRW) 2.18B 2.08B 1.68B 1.31B 1.26B 563M 188M — — —
Bonds payable (KRW) 5.32B 8.05B 7.09B 3.7B — — — — 7.62B 9.49B
Lease liabilities (KRW) — — — 223M 86.9M 313M 227M 164M 198M 133M
Cash and deposits (KRW) 3.3B 19.7B 26.4B 49.2B 5.79B 10.6B 5.52B 7.95B 13.1B 15.2B
Intangible assets (KRW) 13.3B 1.02B 1.1B 1.44B 1.23B 1.25B 590M 595M 629M 556M
Right-of-use assets (KRW) — — — — 136M 309M 220M 157M 207M 137M
Net debt (borrowings + leases - cash) (KRW) -1.12B -6.57B -15.5B -42.9B -4.44B -3.71B 4.19B -1.79B 710M 426M
Cash flow detail
Operating cash flow (KRW) -3.37B -3.69B -5.08B 27.5M -17.9B -8.76B -26.4B -22B -26B 8.3B
Change in receivables (cash effect) (KRW) -6.49B 2.28B -14.3B 15.7B -27B 25.1B -1.2B -148M -31.5B -54.5B
Change in inventories (cash effect) (KRW) 194M -56.9M -117M -14.2M -80M -107M -64.5M -433M -68.7M -45.8M
Change in payables (cash effect) (KRW) 3.89B 111M 720M -824M 2.34B -1.13B 68.3M 832M 343M 7.17B
Share buybacks (cash effect) (KRW) -1.61B — — — — — — — — —
Interest paid (cash effect) (KRW) -289M -244M -164M -176M -103M -104M -303M -410M -270M -237M
Income taxes paid (cash effect) (KRW) -2.93M -25.5M -26.1M -2.99B 4.52M -2.1B 247M 4.6B -942M 1.55B
Share-based compensation (KRW) — 23.9M 130M 134M 310M 57.1M 109M 434M 1.27B 546M
Operating cash flow before change in receivables (KRW) 3.12B -5.97B 9.19B -15.7B 9.1B -33.9B -25.2B -21.9B 5.42B 62.8B
Income detail
Total comprehensive income (KRW) -3.95B -6.27B 5.11B -24.8B -3.18B -26.8B -26.9B -28.5B -2.24B 55.7B
Comprehensive income to owners (KRW) -3.29B -5.52B 4.15B -22.4B -5.18B -27.1B -23.8B -24.3B 477M 53.7B
Provision for credit losses (KRW) 140M -53M -53.1M 651M -108M -2.33M -6.25M -427,261 -130,217 132,173
Credit cost ratio (credit losses / average receivables) (%) 2.9% 1.1% 0.5% 6.6% 0.8% 0.0% 0.5% 0.0% 0.0% 0.0%
Reported Aug 24, 2018 Aug 24, 2018 Mar 29, 2019 Mar 30, 2020 Mar 9, 2021 Mar 18, 2024 Mar 18, 2024 Mar 18, 2024 Mar 19, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

의결권대리행사권유참고서류 Bull 0 Bear 0 Routine
기업설명회(IR)개최 Bull 0 Bear 0 Routine

Prompts

OCT Inc. (ticker 039200), listed in South Korea.

ETFs Holding OCT Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.06% 2,922 $ 74.078K Nov 16, 2026
DEXC 0.01% 921 $ 24.713K Nov 12, 2026
DFSE 0.01% 1,594 $ 42.772K Nov 12, 2026
DFEM 0.01% 22,977 $ 616.542K Nov 12, 2026
DFAE 0.00% 12,988 $ 348.507K Nov 12, 2026
DFAX 0.00% 1,888 $ 50.661K Nov 12, 2026
AVEM 0.00% 198 $ 5,019.67 Nov 16, 2026